CA2459886A1 — 1-glyoxlylamide indolizines for treating cancer
Assigned to Synta Phamaceuticals Corp · Expires 2003-03-20 · 23y expired
What this patent protects
Disclosed is a compound represented by Structural Fonnula (I): Ring A is substituted or unsubstituted and optionally fused to an aryl group. Z1 and Z 2 are independently =0, =S, =N-OR12 or =NR12; R1 and R2 are independently -H, an aliphatic group, a substituted aliphatic group, a…
USPTO Abstract
Disclosed is a compound represented by Structural Fonnula (I): Ring A is substituted or unsubstituted and optionally fused to an aryl group. Z1 and Z 2 are independently =0, =S, =N-OR12 or =NR12; R1 and R2 are independently -H, an aliphatic group, a substituted aliphatic group, an unsubstituted non-aromati c heterocylic group, a substituted non-aromatic heterocylic group, an aryl gro up or a substituted aryl group, provided that R1 and R2 are not both -H. Alternatively, -NR1R2, taken together, is a substituted or unsubstituted non - aromatic nitrogen-containing heterocyclic group or a substituted or unsubstituted nitrogen-containing heteroaryl group. R3 is a substituted or unsubstituted aryl group or a substituted or unsubstituted aliphatic group. X is a covalent bond, -C(R4R5)-, -N(R4)-, -0-, -S-, -S(O)-, -S(0)2-, -C(=O)-, - C(=0)-N(R4)-, or N(R4)-C(=O)-. R4 and R5 are independently -H or a substitut ed or unsubstituted aliphatic group. R12 is -H or a substituted or unsubstitute d alkyl group.
Drugs covered by this patent
- Vascepa (ICOSAPENT ETHYL) · Amarin Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.